Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow-up for Subjects Treated With Gene-Modified T Cells
jRCT2033230513Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2023
01
Overview
Open-label, single-arm trial in Neoplasm, sponsored by Bristol Myers Squibb. Primary endpoints: Risk of delayed adverse events following exposure to gene-modified T cells, Long-term persistence of gene-modified T cells and 3 more. Started Dec 2023; status: recruiting.
02
Conditions
Neoplasm
Beyond the preview
Go deeper on jRCT2033230513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033230513.